Natera (NTRA) announced an expansion of its patent infringement lawsuit against NeoGenomics (NEO) related to its RaDaR tests. On December 10, the District Court for the Middle District of North Carolina granted Natera’s request to include an additional patent in its ongoing lawsuit against NeoGenomics. Natera’s amended complaint now includes U.S. Patent No. 11,319,596, as well as U.S. Patent No. 11,530,454 as previously asserted in the complaint. Natera asserts infringement of the ‘596 and ‘454 patents by the new version of NeoGenomics’ RaDaR test, which tests for molecular residual disease. This follows a December 2023 preliminary injunction and September 2024 permanent injunction ordered by the District Court of NeoGenomics’ previous version of its RaDaR test. Natera is seeking full remedies against NeoGenomics’ current RaDaR test offering, including injunctive relief.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera price target raised to $200 from $160 at JPMorgan
- Natera enrolls 1st patients in SAGITTARIUS clinical trial in colon cancer
- Natera Aligns Executive Chairman’s Pay with Performance
- Natera publishes cfDNA data in Obstetrics & Gynecology
- Guardant says jury unanimously found in favor of company in Natera suit